Reverse merger of Flerie Invest AB (SE) and InDex Pharmaceuticals – SEK 3,073 million

Carnegie acted as financial advisor to Flerie Invest in the reverse merger between Flerie and InDex Pharmaceuticals. Through the transaction, Flerie will become a wholly-owned subsidiary of InDex Pharmaceuticals and Flerie’s shareholders will initially hold approximately 91.9 per cent of the total number of shares and votes in InDex Pharmaceuticals, prior to the completion of the capital raise.